MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock, net of...
$20,716K
Proceeds from issuance of
common stock, net of...
$11,828K
Proceeds from issuance of
insurance loan
$462K
(2.21%↑ Y/Y)
Net cash provided by
financing activities
$29,532K
(229.05%↑ Y/Y)
Canceled cashflow
$3,474K
Net increase in cash
and cash...
$19,973K
(1261.49%↑ Y/Y)
Canceled cashflow
$9,559K
something is missing
-$3,424K
Repayment of insurance
note
$50K
(-87.31%↓ Y/Y)
Change in fair value of
warrant liabilities
$9,784K
(178.11%↑ Y/Y)
Common stock issued in
exchange for services
$972K
(548.00%↑ Y/Y)
Stock-based compensation
$139K
(75.95%↑ Y/Y)
Amortization of operating
right of use assets
$102K
Depreciation and
amortization expense
$71K
Provision (recovery) for
expected credit losses
$25K
something is missing
$213K
Net cash used in
operating activities
-$8,875K
(-18.21%↓ Y/Y)
Net cash used in
investing activities
-$684K
Canceled cashflow
$11,093K
Canceled cashflow
$213K
Net loss
-$16,520K
(28.46%↑ Y/Y)
Purchase of property and
equipment
$897K
Prepaid expense and
other assets
$1,812K
(1068.98%↑ Y/Y)
Accounts payable
-$1,253K
(-150.10%↓ Y/Y)
Accrued expense and
other liabilities
-$232K
(-14.85%↓ Y/Y)
Operating lease
liabilities
-$98K
Account receivable
$50K
Income from equity
method investments
$5K
Back
Back
Cash Flow
NRX Pharmaceuticals, Inc. (NRXP)
NRX Pharmaceuticals, Inc. (NRXP)
source: myfinsight.com